IDH1 and OCT4 in High Grade Astrocytoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: biomarkers analysis.
- Who it may be relevant to
- Registry conditions: High Grade Astrocytoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
IDH1 and OCT4 Markers as a Prognostic Factor in Clinical Outcome of High Grade Astrocytic Glioma
Overview
observation of IDH1 and OCT4 markers level and high grade astrocytoma patients prognosis after excision.
Detailed description
explore the relationship between prognosis and IDH1 and OCT4 biomarkers after high grade astrocytoma excision , according to progression free survival and overall survival , in prospective and retrospective samples.
Interventions
- Other biomarkers analysis
IDH1 and OCT4 markers analysis of surgical specimens of high grade astrocytoma
Primary outcome measures
- IDH1 and OCT4 markers and their relation to postoperative prognosis of high grade astrocytoma patients [Time frame: baseline]
Eligibility criteria
Inclusion criteria
- patients of high grade astrocytic glioma patients fit for surgery
Exclusion criteria
- patients of low grade glioma patients unfit for surgery
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Egypt · 1 center
- Faculty of Medicine of Assiut University — Asyut
Publications
- PubMed
- Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014 Jul;16(7):896-913. doi: 10.1093/neuonc/nou087. PMID 24842956
- Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol. 2016;134:71-95. doi: 10.1016/B978-0-12-802997-8.00005-0. PMID 26948349
- Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. 2007 Nov;25(4):1111-39, x. doi: 10.1016/j.ncl.2007.07.004. PMID 17964028
Identifiers
NCT: NCT06214689 · biomarkers in astrocytoma